SEC Form 4 · accession 0001140361-17-029590

Sienna Biopharmaceuticals, Inc. · SNNA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President & CEO · Director

Period of report

Aug 1, 2017

Accepted (ET)

Aug 1, 2017 · 4:20 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001656328

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Aug 1, 2017	C	14,076	—	A	14,076	I	See Footnote
Common Stock^F1,F3	Aug 1, 2017	C	14,076	—	A	14,076	I	See Footnote
Common Stock^F1,F4	Aug 1, 2017	C	112,614	—	A	112,614	I	See Footnote
Common Stock	holding	—	—		—	553,652	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	D/I
Series A-3 Preferred Stock^F1,F2,F5	—	Aug 1, 2017	C	14,076	D	—	—	Common Stock	14,076	I
Series A-3 Preferred Stock^F1,F3,F5	—	Aug 1, 2017	C	14,076	D	—	—	Common Stock	14,076	I
Series A-3 Preferred Stock^F1,F4,F5	—	Aug 1, 2017	C	112,614	D	—	—	Common Stock	112,614	I

F1The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering.
F2The shares are directly held by Beddingfield Children's Trust fbo Catherine Sara Beddingfield.
F3The shares are directly held by Beddingfield Children's Trust fbo Claire Elizabeth Beddingfield.
F4The shares are directly held by the Beddingfield Family Trust.
F5The expiration date is not relevant to the conversion of these securities.